Fuller (FUL) Q3 2026 Earnings Call Transcript
Fuller (FUL) reported Q3 2026 net revenue of $938M, up 5.2% YoY, with adjusted EBITDA of $187M, up 9% YoY. Adjusted EPS rose 21% to $1.52. Organic revenue grew 4.4%, driven by pricing. Guidance for fiscal 2026 adjusted EBITDA and EPS was updated. Management highlighted Project Quantum Leap savings and the pending AMS acquisition. Risks include chip shortages and supply chain disruptions.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise expectations for FY performance, but execution risk around the AMS acquisition and supply-chain volatility could affect outcomes.
Market read
Earnings and guidance provide actionable insight for investors; sector peers may be impacted by similar pricing and restructuring trends.
What to watch
Potential slowdown in electronics demand and geopolitical supply-chain disruptions remain downside risks.
Background
H.B. Fuller reported Q3 2026 results, showing revenue growth, margin expansion, and updated FY guidance, while outlining restructuring and acquisition plans.
Ticker impact
Q3 2026 earnings release with revenue, EBITDA, EPS numbers and updated FY guidance.
Potential price appreciation if market digests higher guidance and margin expansion.
Guidance lift and improved profitability are material new information for investors.
Market effects
Adhesives sector may see renewed interest due to pricing power and restructuring trends.
Positive outlook for Europe and EIMEA segments could lift regional peers.
Highlights supply-chain dislocation risks affecting broader industrial markets.
Counterpoint
Restructuring costs and integration risk of the Advanced Medical Solutions acquisition could pressure margins.
Key entities
- companyH.B. Fuller Company
Adhesives manufacturer reporting Q3 2026 earnings.
- companyAdvanced Medical Solutions
Pending acquisition target in medical adhesives.

